Scientists from four continents have identified blood proteins that predict lung cancer more than five years before diagnosis, potentially opening new prevention pathways. The international team of over 80 researchers found that inflammation from smoking and air pollution triggers mutations that lead to cancer development.

Researchers discovered early evidence that an existing drug might reduce tumor formation odds, targeting the inflammation process itself. This approach represents a shift toward intercepting cancer before it develops rather than treating advanced disease.

The findings mark early-stage progress toward what public health experts call the 'holy grail' of cancer research. While clinical applications remain distant, the study provides proof that inflammation pathways offer actionable targets for intervention.

Lung cancer claims more lives annually than any other cancer type, making prevention strategies particularly significant. The research team plans to validate their protein markers in larger populations and explore existing anti-inflammatory medications for repurposing.